D 1927
Latest Information Update: 11 Sep 2002
At a glance
- Originator Celltech R&D
- Class Antineoplastics
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration; Cancer; Rheumatoid arthritis
Most Recent Events
- 11 Sep 2002 Discontinued - Phase-I for Rheumatoid arthritis in United Kingdom (unspecified route)
- 11 Sep 2002 Discontinued - Preclinical for Age-related macular degeneration in United Kingdom (unspecified route)
- 20 Aug 2001 Preclinical development for Age-related macular degeneration in United Kingdom (Unknown route)